| 19.05 0.83 (4.56%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.06 | 1-year : | 28.1 |
| Resists | First : | 20.6 | Second : | 24.06 |
| Pivot price | 17.56  |
|||
| Supports | First : | 13.12 |
Second : | 8.5 |
| MAs | MA(5) : | 18.37 |
MA(20) : | 16.54 |
| MA(100) : | 7.83 |
MA(250) : | 6.98 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 75.9 |
D(3) : | 72.2 |
| RSI | RSI(14): 65.3 |
|||
| 52-week | High : | 20.6 | Low : | 2.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KALA ] has closed below upper band by 28.1%. Bollinger Bands are 101.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.5 - 19.63 | 19.63 - 19.74 |
| Low: | 18.09 - 18.23 | 18.23 - 18.34 |
| Close: | 18.86 - 19.08 | 19.08 - 19.26 |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Tue, 23 Sep 2025
HC Wainwright Has Positive View of KALA BIO FY2025 Earnings - MarketBeat
Thu, 18 Sep 2025
Kala Bio schedules 2025 annual shareholder meeting for December 11 - Investing.com
Thu, 18 Sep 2025
Cornea field growing nicely; harvest ahead for Kala? - BioWorld MedTech
Wed, 17 Sep 2025
PERCEPTIVE ADVISORS LLC Increases Stake in Kala Bio Inc - GuruFocus
Fri, 05 Sep 2025
Is KALA BIO On The Verge Of A Pivotal Moment With KPI-012? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 65.5 (%) |
| Shares Short | 420 (K) |
| Shares Short P.Month | 348 (K) |
| EPS | -5.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52 % |
| Return on Equity (ttm) | -708.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -3.2 |
| PEG Ratio | 0 |
| Price to Book value | -39.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|